

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In re Patent Application of

Nicholas S. Bodor et al.

Application No.: 10/551,209

Filed: November 14, 2006

For: ORAL FORMULATIONS OF  
CLADRIBINE



) **MAIL STOP AMENDMENT**

) Group Art Unit: 4173

) Examiner: JONATHAN S LAU

) Confirmation No.: 4092

**REPLY AND AMENDMENT IN RESPONSE TO  
RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated December 6, 2007, please first amend  
the above-identified patent application as follows: